Skip to main content
NCBI home page
Wellcome Open Research logoLink to Wellcome Open Research
. 2016 Nov 15;1:10. [Version 1] doi: 10.12688/wellcomeopenres.9967.1

Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis

Alex Lewin 1,5,a,#, Shea Hamilton 2,b,#, Aviva Witkover 2, Paul Langford 2, Richard Nicholas 3, Jeremy Chataway 4, Charles RM Bangham 2,c
PMCID: PMC5159626  EMSID: EMS70774  PMID: 27996064

Abstract

Background: A major cause of disability in secondary progressive multiple sclerosis (SPMS) is progressive brain atrophy, whose pathogenesis is not fully understood. The objective of this study was to identify protein biomarkers of brain atrophy in SPMS.

Methods: We used surface-enhanced laser desorption-ionization time-of-flight mass spectrometry to carry out an unbiased search for serum proteins whose concentration correlated with the rate of brain atrophy, measured by serial MRI scans over a 2-year period in a well-characterized cohort of 140 patients with SPMS.  Protein species were identified by liquid chromatography-electrospray ionization tandem mass spectrometry.

Results: There was a significant (p<0.004) correlation between the rate of brain atrophy and a rise in the concentration of proteins at 15.1 kDa and 15.9 kDa in the serum.  Tandem mass spectrometry identified these proteins as alpha-haemoglobin and beta-haemoglobin, respectively.  The abnormal concentration of free serum haemoglobin was confirmed by ELISA (p<0.001).  The serum lactate dehydrogenase activity was also highly significantly raised (p<10 -12) in patients with secondary progressive multiple sclerosis. 

Conclusions: An underlying low-grade chronic intravascular haemolysis is a potential source of the iron whose deposition along blood vessels in multiple sclerosis plaques contributes to the neurodegeneration and consequent brain atrophy seen in progressive disease. Chelators of free serum iron will be ineffective in preventing this neurodegeneration, because the iron (Fe 2+) is chelated by haemoglobin.

Keywords: Secondary progressive multiple sclerosis, neurodegeneration, brain atrophy, iron, haemoglobin, proteomics, pathogenesis

Introduction

In multiple sclerosis (MS), progressive disease develops in over half of those who present with an initial relapsing phase – secondary progressive MS (SPMS) – but can also present as primary progressive MS (PPMS). Progressive MS, for which there is no clear disease-modifying treatment 1– 3, accounts for much of the disability and the cost of MS to both the person and the community 4.

Unlike relapsing-remitting MS (RRMS), where an inflammatory response involving the adaptive immune system leads to episodic neurological deficits, in progressive MS neuroaxonal loss leads to an increasing neurological deficit and brain atrophy 5, 6. However, in all forms of the disease, both the initiating events and the mechanisms of pathogenesis remain uncertain 5. Pseudoatrophy may account for some loss of brain volume 7, but brain atrophy has also been associated with changes in neurofilament levels 8 and sodium metabolism 9.

The objective of the present study was to use an unbiased, high-throughput technique to identify protein biomarkers of brain atrophy in a longitudinal cohort of patients with SPMS. We used surface-enhanced laser desorption-ionization time-of-flight (SELDI-TOF) mass spectrometry to analyse serial serum samples from the population that participated in the MS-STAT study (described below) 1, to identify proteins whose abundance was associated with MRI-measured brain atrophy rate. Serum proteomics in MS has previously been investigated in small cross-sectional studies to compare relapsing MS and progressive disease 10– 12. However, these previous studies were neither designed nor powered to identify correlates of neurodegeneration in SPMS.

We found that the rate of brain atrophy in this cohort was associated with an increase in the concentration of free haemoglobin in the serum. This association was independent of the beneficial effect of simvastatin treatment, which remained significant in the present analysis. An ELISA assay confirmed the presence of abnormal concentrations of free haemoglobin in the serum of patients with SPMS. In addition, the serum lactate dehydrogenase (LDH) activity was significantly greater in patients with SPMS than in three different groups of control subjects. These results suggest that chronic intravascular haemolysis releases haemoglobin into the serum in SPMS; we postulate that this haemoglobin is a source of the abnormal iron deposition along blood vessels in the central nervous system that is associated with neurodegeneration in progressive MS.

Methods

Ethical approval

The study was done in accordance with Good Clinical Practice and the Declaration of Helsinki. The protocol was approved by the UK National Research Ethics Service (Berkshire Research Ethics Committee; reference 07/Q1602/73), and every patient gave written informed consent before entering the study.

Subjects

The MS-STAT clinical trial was registered with ClinicalTrials.gov (NCT00647348) and has been described in detail elsewhere 1. In this phase 2 placebo-controlled double-blind trial, 140 patients with SPMS were randomized 1:1 to simvastatin 80 mg/day (40 mg for the first month) or matched placebo. The patients were in trial for 2 years. The primary outcome was change in whole brain volume as measured by the Brain Boundary Shift Integral (BBSI), with MRI data acquired at baseline, 12 months and 25 months; the last MRI scan (25 months) was carried out 1 month after last medication to minimize any potential artefactual changes in volume 1. Simvastatin treatment resulted in a highly statistically significant 43% reduction in the annualized rate of brain atrophy 1, and significant changes were also seen in certain clinician- and patient-reported outcome measures. As control groups in the haemoglobin assays, we studied healthy adult volunteers (n=20); patients with human T-lymphotropic virus (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP), which closely resembles chronic spinal forms of multiple sclerosis (n=20); and asymptomatic HTLV-1 carriers (n=20).

Protein profiling of serum by SELDI-TOF mass spectrometry

SELDI-TOF mass spectrometry was performed on 475 serum samples collected at baseline, 6 month, 12 months and 24 months. Samples were randomized, and staff were blinded to the treatment arms. CM10 ProteinChip arrays (Bio-Rad Laboratories) were primed with binding buffer (50 mM ammonium acetate, 0.01% Triton X-100, pH 4·0) and incubated at room temperature (RT) for 5 min. A 1:10 dilution of serum in binding buffer was then applied to the array and incubated at RT for 1 hr. The arrays were washed twice with binding buffer and deionized water. Saturated sinapinic acid (0.7 µL) was applied twice to each spot on the arrays. Time-of-flight spectra were generated using a PCS-4000 mass spectrometer (Bio-Rad). Low-range spectra (mass/charge (m/z) ratio 0 – 20,000) were obtained at a laser energy of 3000 nJ, with a focus mass of 6000 and the matrix attenuated to 1000. High-range spectra (m/z 10,000 – 75,000) were obtained at a laser energy of 3900 nJ, with a focus mass of 30,000 and the matrix attenuated to 10,000. Mass accuracy was calibrated externally using All-in-One Peptide or Protein molecular mass standards (Bio-Rad).

Proteomics data processing

Spectra were analysed using ProteinChip Data Manager (Bio-Rad version 4.1.0) and normalized using total ion current. Peaks were auto-detected using a peak threshold of 12.5% and a mass window of 0.3%, and the resulting data were converted for subsequent analysis using R software. The abundance (intensity) of a given protein peak was quantified as the area under the peak; peak intensities were log-transformed before analysis. After exclusion of one contaminated sample and 4 technical failures, the proteomics data consisted of 470 spectra from 138 patients.

Protein enrichment and identification

Ten µL serum were applied to Top 12 Abundant Protein Depletion Spin Columns (Thermo Scientific Pierce) according to the manufacturer’s protocol. Five hundred µL of the eluate were concentrated on a 3 kDa molecular weight cut-off column (Amicon) in 25 mM Tris-HCl, pH 8.0. Twenty µL of depleted serum were separated by 1D SDS-PAGE on an 18% Tris-glycine denaturing gel (TGX, Bio-Rad) at 150 V for 70 min and compared against SeeBlue Plus 2 pre-stained protein standard (Life Technologies). The gel was rinsed 5 times with deionized water and stained overnight in See Band staining solution (Gene Bio-Application Ltd.) A band corresponding to 15 to 16 kDa was excised and an in-gel trypsin digest 13 was carried out.

Samples were analysed by nanoscale liquid chromatography-electrospray ionization tandem mass spectrometry (LC-MS/MS), using a nanoAcquity UPLC system (Waters MS Technologies, Manchester, UK). Peptide identification was performed using ProteinLynx Global SERVER v3.1 (Waters).

Serum haemoglobin concentration

Free haemoglobin levels were assayed by ELISA (Abcam ab157707) according to the manufacturer’s protocol. Samples were analysed in random order, and staff were blinded to the treatment arms. Absorbance was measured at 450 nm on a SpectraMax microplate reader (Molecular Devices).

Serum lactate dehydrogenase (LDH) activity

Serum LDH activity was assayed by the conversion of lactate to pyruvate, using the absorption of light at 340 nm by the reaction product NADH (Abbott Laboratories, ref. 7D69).

Statistics

All statistical models were carried out using R 3.2.1 software 14. To test for associations between SELDI-TOF mass spectrometry peak intensity changes and treatment group, linear regression models were fitted separately for each spectral peak at each follow-up time (6, 12 and 24 months), modelling log(peak intensity change from baseline) as a function of baseline log(peak intensity), treatment group, and the five randomization variables (age, gender, EDSS [Expanded Disability Severity Scale], neuroscience centre, and assessing physician).

To test for associations between peak intensity changes and brain volume changes, for each pair of time points (0–12 months, 0–25 months and 12–25 months) the BBSI was compared with the change in each peak intensity. Linear regression was used to model the log(change in peak intensity) as a function of BBSI (expressed as a percentage of baseline whole-brain volume), adjusted for baseline log(peak intensity), MRI centre, and the five randomization variables.

For both treatment and brain volume analyses, sensitivity analysis was carried out using repeated-measures models including all four time points. Protein peaks whose regression coefficients differed significantly from zero (Wald test) were selected for further analysis. To take into account multiple testing, the p-value for each peak was converted into the False Discovery Rate (FDR: expected proportion of false positives) for that p-value threshold, using the R package fdrtool 15. Peaks at FDR ≤ 0.2 were retained for further analysis.

The results of the haemoglobin ELISA and the serum LDH assay were analysed using two-tailed Mann-Whitney tests to test for pairwise differences between the subject groups.

Results

Intensity of specific protein peaks was associated with change in brain volume

Expression-difference mapping of all longitudinal serum samples (peak threshold of 12.5%; mass window of 0.3% minimum) resulted in detection of 145 peaks that were differentially expressed within individual subjects over time.

To determine whether changes in protein levels (SELDI-TOF peak intensity) were associated with simvastatin treatment, we ran regression models for the change in each protein peak intensity vs. treatment status, adjusting for the 5 randomization variables and MRI centre. No association remained significant after adjusting for multiple comparisons (the lowest level at which the FDR could be controlled was 0.3).

We next ran regression models for change in protein intensity v. brain volume loss, for each interval in which the BBSI was measured (0 to 12 months; 12 to 25 months) and over the whole trial period (0 to 25 months). The changes in intensity of peaks at m/z = 25,110 and 25,402 were significantly associated with the change in brain volume between baseline and 12 months (p=0.001, corresponding to FDR = 0.08). The regression coefficients for the association were negative, i.e. an increase in these protein intensities was associated with a smaller decrease in brain volume. The change in intensity of the peaks at m/z = 15,141 and 15,885 between baseline and 25 months was significant in each case (p=0.003 and 0.001 respectively), corresponding to a FDR of 0.2. For these peaks the regression coefficients were positive, i.e. an increase in these peaks was associated with a larger decrease in brain volume ( Figure 1). There were no significant regression coefficients for the 12 to 25 month time period. Repeated-measures models for the whole time period of the trial also identified the peaks at m/z = 15,141 and 15,885 as significant at an FDR of 0.2.

Figure 1. Change in intensity of 15.1 kDa peak correlated with rate of brain atrophy.

Figure 1.

Open in a new tab

Normalized log(change in intensity of 15.1 kDa peak between baseline and 2-year follow-up) versus percentage decrease in brain volume between baseline and 2 years. Solid line shows the best fit from the linear regression model (regression coefficient = 0.12, p=0·001). Protein ratios were normalized to all other covariates, using the linear regression model. Crosses represent treated individuals, circles represent untreated individuals. The correlation with the 15.9 kDa peak was closely similar (regression coefficient = 0.12, p=0·001).

Multiple regression analysis, modelling brain volume change as a function of protein peak intensity, treatment status, and the five randomization variables and MRI centre as covariates confirmed ( Table 1) that simvastatin treatment and the protein peak intensity were independently associated with the rate of brain atrophy.

Table 1. Multiple linear regression analysis of the association between change in brain volume and change in the peak intensity of the proteins whose changes were found to be significantly correlated with change in brain volume.

Beta = regression coefficient. The model is adjusted for the 5 randomization variables and MRI centre.

m/z 15885 (0 to 25 months) m/z 15141 (0 to 25 months)
Beta (95% CI) p Beta (95% CI) p
protein 0.83 (0.33, 1.33) 0.001 0.75 (0.29, 1.22) 0.002
treatment -0·62 (-1.06, -0.19) 0.005 -0.60 (-1.03, -0.17) 0.007
m/z 25110 (0 to 12 months) m/z 25402 (0 to 12 months)
Beta (95% CI) p Beta (95% CI) p
protein -0.99 (-1.72, -0.26) 0.008 -0.73 (-1.37, -0.09) 0.025
treatment -0.26 (-0.56, -0.04) 0.090 -0.27 (-0.58, -0.04) 0.083
Open in a new tab

The multiple regression model ( Table 1) explained 25% of the observed variation in the rate of brain atrophy over the two-year observation period; the protein peak at 15.1 kDa alone explained 10% of this variation. The regression coefficient of -0.6 for simvastatin treatment indicates a mean difference in brain atrophy rate between treatment groups of -0.6% over the 2-year trial period; this estimate (-0.3%/year) is consistent with the rate of -0.25%/year previously reported in the MS-STAT trial 1. The regression coefficient of 0.75 for BBSI v. protein change means that two patients whose protein increases differ by 30% have an expected difference in brain atrophy rate of 0.1% over two years (the patient with higher increase in protein 15.1kDa expects a greater decrease in brain volume).

Identification of proteins associated with brain atrophy

After enrichment, the intensity of the protein peaks at 25.1 kDa and 25.4 kDa remained insufficient to allow their isolation and identification. However, the peaks at 15.1 kDa and 15.9 kDa remained at high intensities and distinct from nearby peaks ( Figure 2). LC-MS/MS identified twenty-six peptide fragments matching human proteins: 15 fragments corresponded to human α-haemoglobin and the remaining 11 fragments corresponded to β-haemoglobin ( Table 2; Supplementary Table 1). Of the remaining 364 sequence matches (after exclusion of bacterial sequences and the common contaminant keratin), the top 360 were partial matches to haemoglobin subunits of other mammalian species.

Figure 2. SELDI-TOF mass spectrometry spectra of 15.1 kDa and 15.9 kDa peaks.

Figure 2.

Open in a new tab

( A.) Following enrichment on Top 12 Protein Depletion column and ( B.) Concentration of eluate on 3 kDa molecular weight cutoff column.

Table 2. Identification of peptide fragments from 15.1 kDa and 15.9 kDa protein peaks, using LC-MS/MS.

*oxidation of M(1). **oxidation of M(15).

Peak m/z Protein name Accession no.
(UniProt)		 PLGS
score		 Peptide matches
1 15,141 Haemoglobin
alpha		 P69905 2049 (R)VDPVNFK(L)
(R)MFLSFPTTK(T) *
(K)VGGHAAEYGAEALER(M)
(R)MFLSFPTTK(T)
2 15,885 Haemoglobin
beta		 P68871 2579 (R)FFESFGDLSTPDAVMGNPK(V) **
(R)LLVVYPWTQR(F)
(K)EFTPPVQAAYQK(V)
(R)FFESFGDLSTPDAVMGNPK(V)
(K)LHVDPENFR(L)
Open in a new tab

ELISA confirms the presence of free serum haemoglobin in MS patients

We assayed free haemoglobin by ELISA in MS patients (n=20) and in three control groups (n=20 in each group; Materials and Methods). The results ( Figure 3A) showed significantly higher concentrations of free haemoglobin in the serum from MS patients, when compared to each control group (p<0.001 in each comparison; Mann-Whitney). Of the 20 MS patients assayed, 17 had a serum haemoglobin concentration greater than the mean + 2 standard errors of the healthy adult controls. No significant difference was observed between the three control groups.

Figure 3. Free serum haemoglobin and lactate dehydrogenase are raised in secondary progressive multiple sclerosis.

Figure 3.

Open in a new tab

A. Serum haemoglobin concentration measured by ELISA in asymptomatic carriers of HTLV-1 (AC), patients with HTLV-1-associated myelopathy (HAM), uninfected, healthy controls (HC), and patients with secondary progressive MS. Log [haemoglobin] by ELISA was significantly correlated with log(peak intensity): r = 0.52; p = 0.02; linear regression. B. Serum lactate dehydrogenase (LDH) activity in the same groups of subjects.

Abnormally high serum LDH activity in MS patients

The presence of free haemoglobin in the serum in MS patients suggested a degree of intravascular haemolysis in these individuals. To seek corroborative evidence of haemolysis, we assayed the serum LDH activity. The median LDH activity in the patients with MS was significantly greater than that in each of the three control groups ( Figure 3B; p<10 -12 in each case; Mann-Whitney); no significant difference was found between the three control groups, in each of which the LDH was within the normal range.

The mean erythrocyte count, haematocrit and total blood haemoglobin in the cohort were within the normal range (see Data availability), and there was no association between these parameters and the rate of brain atrophy.

Discussion

The characteristic pathological feature of early, active multiple sclerosis lesions is primary demyelination, with partial preservation of axons. But the dominant feature in progressive disease is neurodegeneration, which results in brain atrophy. Factors associated with this neurodegeneration 5 include microglial activation, chronic oxidative injury, mitochondrial damage in axons, and iron accumulation. A strong correlate of neurodegeneration in MS is abnormal iron deposition in both grey and white matter in MS, especially along veins and venules in cerebral MS plaques 16, 17. Iron can potentiate oxidative damage by generating hydroxyl radicals by the Fenton reaction. The extent of iron accumulation, as indicated by T2 signal hypointensity on MRI, is correlated with disease progression, lesion accumulation and cell death of oligodendrocytes 18– 20. The extent of iron deposition is greater in SPMS than in relapsing-remitting disease 18.

The source of this abnormal iron deposited in the central nervous system in MS is unknown. Iron is liberated from damaged oligodendrocytes and myelin 21 and accumulates in macrophages and microglia at the margin of active lesions, but it remains unclear whether this is the principal source of the iron that accumulates in the vessel walls and perivascular space. Bamm and Harauz 22 proposed that chronic extravasation of red blood cells is a source of the abnormal iron deposits; however, neuropathological evidence does not show frequent or widespread extravascular erythrocytes in the MS brain.

The results presented here show that a rise in the concentration of free haemoglobin in the serum was associated with the rate of brain atrophy in this cohort of patients with SPMS. This effect was independent of the beneficial treatment effect of simvastatin, because there was no association between free haemoglobin concentration and simvastatin treatment. Since a successful response to simvastatin treatment was not associated with the free serum haemoglobin concentration, we infer that the change in free serum haemoglobin was not a consequence of brain atrophy but preceded brain atrophy in the causal pathway.

These results suggest the hypothesis that chronic, low-grade intravascular haemolysis releases haemoglobin into the serum, which is then translocated into the CNS parenchyma across the impaired blood-brain barrier and potentiates oxidative damage to oligodendrocytes. Cytotoxicity by free haemoglobin can be mediated by intact haemoglobin itself, by haem, or by iron, especially as Fe 2+ 22. Free haemoglobin is degraded by haem oxygenase-1 (HO-1), producing biliverdin and Fe 2+ ions. HO-1 is upregulated in glia by oxidative stress, and HO-1 is expressed in oligodendrocytes in actively demyelinating areas in MS, but not in two other CNS diseases, human acute disseminated leukoencephalomyelitis (ADEM) or murine experimental allergic encephalomyelitis (EAE) 23. Stahnke et al. 23 proposed that the role of stress-induced HO-1 is protective initially, whereas chronic upregulation might cause oligodendrocyte death.

The observation ( Figure 3B) of abnormally high serum LDH activity is consistent with the presence of haemolysis in these patients. LDH is present in all cell types, and serum LDH is raised in many inflammatory conditions; however, erythrocytes are particularly rich in LDH, and serum LDH is a sensitive marker of haemolysis. The notion that chronic intravascular haemolysis might serve as a source of the iron deposited in MS is also consistent with earlier reports of abnormal fragility of erythrocytes. Erythrocytes from patients with MS, especially those with active disease, are abnormally susceptible to lysis by both mechanical stress 24 and osmotic stress 25. The causes of this erythrocyte fragility remain to be identified. Possible artefactual causes of haemolysis, such as venepuncture, cannot explain the significant association observed here between brain atrophy and free serum haemoglobin.

If intravascular haemolysis indeed occurs in SPMS, the rate of red cell destruction is insufficient to reduce the total blood haemoglobin, which remained within normal limits in this cohort. Neurodegeneration is not a feature of other chronic haemolytic conditions, such as spherocytosis or elliptocytosis; however, in these conditions the blood-brain barrier is intact, and most erythrocyte destruction occurs in the spleen, where efficient phagocytosis may prevent the release of the toxic breakdown products into the circulation.

Polymorphisms in genes encoding iron-binding and iron-transporting proteins are associated with disability, disease severity and early progression in MS 26. Rithidech et al. 27 used 2D electrophoresis to identify plasma biomarkers in paediatric MS: the haem-binding protein haemopexin was 1 of 12 proteins found to be upregulated in 9 MS patients. Robotti et al. 28 identified an alteration in the ratio of isoforms of haptoglobin (which bind free haemoglobin) in MS.

These results do not suggest that free serum haemoglobin concentration is useful in the differential diagnosis of neurological disease; rather, they identify a potential contributor to the pathogenesis of neurodegeneration in progressive multiple sclerosis.

Previous studies of serum iron have shown normal concentrations in the serum in patients with MS 29; however, standard assays of free serum iron do not detect iron that is sequestered in haemoglobin. Iron chelation has been proposed as a therapy to approach to reduce neurodegeneration in MS. However, if an important source of iron is free serum haemoglobin, standard iron-chelating agents such as desferrioxamine will be ineffective, again because the iron is sequestered in haemoglobin 30. Scavengers of haemoglobin and haemin 31 might be more effective.

Data availability

Zenodo: Raw data for SELDI-TOF low range from article: Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis, http://doi.org/10.5281/zenodo.160737 32

Zenodo: Raw data for SELDI-TOF high range from article: Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis, http://doi.org/10.5281/zenodo.160743 33

Zenodo: Nano LC MS-MS peptide matches from article: Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis, http://doi.org/10.5281/zenodo.160744 34

Zenodo: Raw data for RBC, Hb and haematocrit from article: Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis, http://doi.org/10.5281/zenodo.161532 35

Acknowledgements

We thank the participants in the MS-STAT trial; Alan Courtney and the staff of the Clinical Biochemistry Laboratory of Imperial College NHS Hospital Trust for carrying out the LDH assays; and Hal Drakesmith for helpful discussion. The analysis of the MRI data in the previously reported MS-STAT trial was carried out by Nick Fox (University College London), Jennifer Nicholas and Chris Frost (London School of Hygiene and Tropical Medicine).

Funding Statement

This work was supported by the Wellcome Trust [100291]; Medical Research Council [MR K019090]; National Institute of Health Research; University College London Hospitals/UCL Biomedical Research Centre.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

[version 1; referees: 1 approved, 2 approved with reservations]

Supplementary material

Supplementary Table 1. Protein peaks associated with brain atrophy: identification by liquid chromatography-electrospray ionization tandem mass spectrometry. Relative molecular mass, protein score and identity of the genes with sequence matches to peptide fragments from the protein peaks that were significantly correlated with the rate of brain atrophy. The common contaminant keratin and partial matches to contaminating bacterial sequences were excluded.

Click here for additional data file. (245.5KB, tgz)

.

References

  • 1. Chataway J, Schuerer N, Alsanousi A, et al. : Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet. 2014;383(9936):2213–21. 10.1016/S0140-6736(13)62242-4 [DOI] [PubMed] [Google Scholar]
  • 2. Kappos L, Li D, Calabresi PA, et al. : Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378(9805):1779–87. 10.1016/S0140-6736(11)61649-8 [DOI] [PubMed] [Google Scholar]
  • 3. Ontaneda D, Fox RJ, Chataway J: Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol. 2015;14(2):208–23. 10.1016/S1474-4422(14)70264-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Plantone D, De Angelis F, Doshi A, et al. : Secondary Progressive Multiple Sclerosis: Definition and Measurement. CNS drugs. 2016;30(6):517–26. 10.1007/s40263-016-0340-9 [DOI] [PubMed] [Google Scholar]
  • 5. Mahad DH, Trapp BD, Lassmann H: Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14(2):183–93. 10.1016/S1474-4422(14)70256-X [DOI] [PubMed] [Google Scholar]
  • 6. Reynolds R, Roncaroli F, Nicholas R, et al. : The neuropathological basis of clinical progression in multiple sclerosis. Acta Neuropathol. 2011;122(2):155–70. 10.1007/s00401-011-0840-0 [DOI] [PubMed] [Google Scholar]
  • 7. Kapoor R, Furby J, Hayton T, et al. : Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol. 2010;9(7):681–8. 10.1016/S1474-4422(10)70131-9 [DOI] [PubMed] [Google Scholar]
  • 8. Gnanapavan S, Grant D, Morant S, et al. : Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progression. PLoS One. 2013;8(8):e70019. 10.1371/journal.pone.0070019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Paling D, Solanky BS, Riemer F, et al. : Sodium accumulation is associated with disability and a progressive course in multiple sclerosis. Brain. 2013;136(Pt 7):2305–17. 10.1093/brain/awt149 [DOI] [PubMed] [Google Scholar]
  • 10. Liguori M, Qualtieri A, Tortorella C, et al. : Proteomic profiling in multiple sclerosis clinical courses reveals potential biomarkers of neurodegeneration. PLoS One. 2014;9(8):e103984. 10.1371/journal.pone.0103984 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Teunissen CE, Koel-Simmelink MJ, Pham TV, et al. : Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry. Mult Scler. 2011;17(7):838–50. 10.1177/1352458511399614 [DOI] [PubMed] [Google Scholar]
  • 12. Tremlett H, Dai DL, Hollander Z, et al. : Serum proteomics in multiple sclerosis disease progression. J Proteomics. 2015;118:2–11. 10.1016/j.jprot.2015.02.018 [DOI] [PubMed] [Google Scholar]
  • 13. Shevchenko A, Wilm M, Vorm O, et al. : Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem. 1996;68(5):850–8. 10.1021/ac950914h [DOI] [PubMed] [Google Scholar]
  • 14. R Core Team: R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.2013. Reference Source [Google Scholar]
  • 15. Strimmer K: fdrtool: a versatile R package for estimating local and tail area-based false discovery rates. Bioinformatics. 2008;24(12):1461–2. 10.1093/bioinformatics/btn209 [DOI] [PubMed] [Google Scholar]
  • 16. Adams CW: Perivascular iron deposition and other vascular damage in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1988;51(2):260–5. 10.1136/jnnp.51.2.260 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Williams R, Buchheit CL, Berman NE, et al. : Pathogenic implications of iron accumulation in multiple sclerosis. J Neurochem. 2012;120(1):7–25. 10.1111/j.1471-4159.2011.07536.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Bakshi R, Shaikh ZA, Janardhan V: MRI T2 shortening ('black T2') in multiple sclerosis: frequency, location, and clinical correlation. Neuroreport. 2000;11(1):15–21. 10.1097/00001756-200001170-00004 [DOI] [PubMed] [Google Scholar]
  • 19. Brass SD, Benedict RH, Weinstock-Guttman B, et al. : Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis. Mult Scler. 2006;12(4):437–44. 10.1191/135248506ms1301oa [DOI] [PubMed] [Google Scholar]
  • 20. Neema M, Arora A, Healy BC, et al. : Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging. 2009;19(1):3–8. 10.1111/j.1552-6569.2008.00296.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Hametner S, Wimmer I, Haider L, et al. : Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol. 2013;74(6):848–61. 10.1002/ana.23974 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Bamm VV, Harauz G: Hemoglobin as a source of iron overload in multiple sclerosis: does multiple sclerosis share risk factors with vascular disorders? Cell Mol Life Sci. 2014;71(10):1789–98. 10.1007/s00018-014-1570-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Stahnke T, Stadelmann C, Netzler A, et al. : Differential upregulation of heme oxygenase-1 (HSP32) in glial cells after oxidative stress and in demyelinating disorders. J Mol Neurosci. 2007;32(1):25–37. 10.1007/s12031-007-0005-8 [DOI] [PubMed] [Google Scholar]
  • 24. Schauf CL, Frischer H, Davis FA: Mechanical fragility of erythrocytes in multiple sclerosis. Neurology. 1980;30(3):323–5. 10.1212/WNL.30.3.323 [DOI] [PubMed] [Google Scholar]
  • 25. Kurantsin-Mills J, Samji N, Moscarello MA, et al. : Comparison of membrane structure, osmotic fragility, and morphology of multiple sclerosis and normal erythrocytes. Neurochem Res. 1982;7(12):1523–40. 10.1007/BF00965095 [DOI] [PubMed] [Google Scholar]
  • 26. Gemmati D, Zeri G, Orioli E, et al. : Polymorphisms in the genes coding for iron binding and transporting proteins are associated with disability, severity, and early progression in multiple sclerosis. BMC Med Genet. 2012;13:70. 10.1186/1471-2350-13-70 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Rithidech KN, Honikel L, Milazzo M, et al. : Protein expression profiles in pediatric multiple sclerosis: potential biomarkers. Mult Scler. 2009;15(4):455–64. 10.1177/1352458508100047 [DOI] [PubMed] [Google Scholar]
  • 28. Robotti A, Natale M, Albo AG, et al. : Acute-phase proteins investigation based on lectins affinity capture prior to 2-DE separation: application to serum from multiple sclerosis patients. Electrophoresis. 2010;31(17):2882–93. 10.1002/elps.201000171 [DOI] [PubMed] [Google Scholar]
  • 29. LeVine SM, Lynch SG, Ou CN, et al. : Ferritin, transferrin and iron concentrations in the cerebrospinal fluid of multiple sclerosis patients. Brain Res. 1999;821(2):511–5. 10.1016/S0006-8993(98)01360-2 [DOI] [PubMed] [Google Scholar]
  • 30. Weigel KJ, Lynch SG, LeVine SM: Iron chelation and multiple sclerosis. ASN Neuro. 2014;6(1):e00136. 10.1042/AN20130037 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Schaer DJ, Buehler PW, Alayash AI, et al. : Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood. 2013;121(8):1276–84. 10.1182/blood-2012-11-451229 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Lewin A, Hamilton S, Witkover A, et al. : Raw data for SELDI-TOF low range from article: Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis. Zenodo. 2016. Data Source [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Lewin A, Hamilton S, Witkover A, et al. : Raw data for SELDI-TOF high range from article: Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis. Zenodo. 2016. Data Source [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Lewin A, Hamilton S, Witkover A, et al. : Nano LC MS-MS peptide matches from article: Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis. Zenodo. 2016. Data Source [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Lewin A, Hamilton S, Witkover A, et al. : Raw data for RBC, Hb and haematocrit from article: Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis. Zenodo. 2016. Data Source [DOI] [PMC free article] [PubMed] [Google Scholar]
Wellcome Open Res. 2016 Dec 12. doi: 10.21956/wellcomeopenres.10742.r17822

Referee response for version 1

Franz Fazekas 1, Michael Khalil 2

This is an interesting study linking an increase of serum hemoglobin to brain atrophy in patients with secondary progressive multiple sclerosis. In this study 140 patients have been included, who were initially recruited for the phase 2, placebo-controlled MS-STAT trial, investigating the effect of simvastatin on brain volume loss after 2 years of treatment. A total of 475 serum samples collected at baseline, 6 months, 12 and 24 months have been analyzed using an unbiased search for protein profiles by SELDI-TOF mass spectrometry. Brain volume changes were measured by MRI Brain Boundary Shift Integral (BBSI) at baseline, 12 months and 25 months.

An increased abundance of serum proteins at 15.1 kDa and 15.9 kDa were significantly correlated to the rate of brain atrophy after 2 years. These proteins have then been identified as alpha-hemoglobin and beta hemoglobin using tandem mass spectrometry. In addition, higher serum hemoglobin concentration in SPMS patients compared to controls has been confirmed using ELISA. The authors further studied serum lactate dehydrogenase activity, which has also been shown to be significantly increased in SPMS compared to controls.

It was concluded that a low-grade chronic intravascular hemolysis, which is a potential source of iron whose deposition along blood vessels in multiple sclerosis plaques contributes to neurodegeneration and brain atrophy in progressive MS.

The results of this study are intriguing and underline other reports on the possible implication of hemoglobin in the pathogenesis of multiple sclerosis, reviewed in Altinoz et al. (2016). Lewin et al. hypothesize that increased serum levels of free hemoglobin may trigger iron deposition along blood vessels in MS, which could then propagate neurodegeneration and brain atrophy. While this speculation brings in a new idea, it appears biologically difficult how these processes (e.g. iron deposition along blood vessels in MS lesions and cortical atrophy) should be so tightly linked in time if at all. Otherwise increased iron deposition has been shown to occur in MS using several MRI techniques although due to technical reasons robust quantification of brain iron deposition is currently limited to deep gray matter areas (Ropele et al. 2011). Longitudinal studies are still scarce, but a recent report indicates that increased brain iron deposition is more pronounced in early phases of the disease (Khalil et al. 2015). Less information exists on progressive forms of MS but one would speculate that the damaging effects from iron deposition are a long-standing rather than an immediate effect as suggested by Lewin et al.. Observed correlation thus are likely not able to clarify if and to which extent increased brain iron deposition really amplifies neurodegeneration in MS or merely reflects an epiphenomenon of the disease. There is also some evidence for alterations of iron related proteins in CSF and serum of MS patients, including transferrin (Khalil et al. 2014)  and lipocalin 2 (Khalil et al. 2016), and which may contribute to iron accumulation.

Reiterating some of the concerns and comments of the other reviewers we thus see the need to put reported findings in a more cautious context. Also some methodological issues deserve clarification.

Major comments

  • The authors should rather use the term “correlated” instead of “associated” and discuss that presented observations do not prove causality as outlined above.

  • For the same reasons the authors should also avoid to embark on therapeutic speculations.

  • The authors state that they analyzed 475 serum samples at different time points (0, 6, 12 and 24 months), however they do not indicate later on how they used the time point a 6 months. Please clarify.

  • It is not clear why the confirmative analysis of free serum hemoglobin using ELISA has only been performed in 20 SPMS patients. It would have been advantageous and the authors a strongly encouraged to determine free serum hemoglobin in all 475 serum to see if increased free serum hemoglobin as determined by ELISA was also correlated with increased brain atrophy.

  • The Discussion should also reflect still existing uncertainties in a more comprehensive manner.

 

Minor comments

  • In Figure 3, p-values (corrected for multiple comparisons) of group differences should be included.

  • In Figure legend 3 it is mentioned that “...Log [haemoglobin] by ELISA was significantly correlated with log(peak intensity): r = 0.52; p = 0.02; linear regression...”. For better understanding and reading this information should be presented by a separate scatter plot.

We have read this submission. We believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.

References

  • 1. Altinoz MA, Ozcan EM, Ince B, Guloksuz S: Hemoglobins as new players in multiple sclerosis: metabolic and immune aspects. Metab Brain Dis.2016;31(5) : 10.1007/s11011-016-9845-7 983-92 10.1007/s11011-016-9845-7 [DOI] [PubMed] [Google Scholar]
  • 2. Khalil M, Langkammer C, Pichler A, Pinter D, Gattringer T, Bachmaier G, Ropele S, Fuchs S, Enzinger C, Fazekas F: Dynamics of brain iron levels in multiple sclerosis: A longitudinal 3T MRI study. Neurology.2015;84(24) : 10.1212/WNL.0000000000001679 2396-402 10.1212/WNL.0000000000001679 [DOI] [PubMed] [Google Scholar]
  • 3. Khalil M, Riedlbauer B, Langkammer C, Enzinger C, Ropele S, Stojakovic T, Scharnagl H, Culea V, Petzold A, Teunissen C, Archelos JJ, Fuchs S, Fazekas F: Cerebrospinal fluid transferrin levels are reduced in patients with early multiple sclerosis. Mult Scler.2014;20(12) : 10.1177/1352458514530020 1569-77 10.1177/1352458514530020 [DOI] [PubMed] [Google Scholar]
  • 4. Khalil M, Renner A, Langkammer C, Enzinger C, Ropele S, Stojakovic T, Scharnagl H, Bachmaier G, Pichler A, Archelos JJ, Fuchs S, Seifert-Held T, Fazekas F: Cerebrospinal fluid lipocalin 2 in patients with clinically isolated syndromes and early multiple sclerosis. Mult Scler.2016;22(12) : 10.1177/1352458515624560 1560-1568 10.1177/1352458515624560 [DOI] [PubMed] [Google Scholar]
  • 5. Ropele S, de Graaf W, Khalil M, Wattjes MP, Langkammer C, Rocca MA, Rovira A, Palace J, Barkhof F, Filippi M, Fazekas F: MRI assessment of iron deposition in multiple sclerosis. J Magn Reson Imaging.2011;34(1) : 10.1002/jmri.22590 13-21 10.1002/jmri.22590 [DOI] [PubMed] [Google Scholar]
Wellcome Open Res. 2016 Nov 21. doi: 10.21956/wellcomeopenres.10742.r17825

Referee response for version 1

George Harauz 1, Vladimir V Bamm 1

Summary – This article describes a proteomics analysis of serum proteins derived from 140 patients with secondary progressive multiple sclerosis (MS), 20 healthy adult volunteers, 20 patients with human T‐lymphotropic virus (HTLV‐1) causing symptoms resembling spinal MS, and 20  asymptomatic HTLV‐1 carriers. Half of the MS patients were undergoing treatment with simvastatin,  a drug used to lower blood cholesterol and shown to have immunomodulatory and anti-inflammatory properties. Protein profiling of sera was achieved by mass spectrometry of 475 serum samples collected at 0, 12, and 24 months. (A 6‐month time point is mentioned in some places and is queried below). The MS patients had concurrent MRI scans at 0, 12, and 25 months to measure whole brain volume (BBSI – brain boundary shift integral), presumably amongst other measures. Serum samples were “enriched” and analysed by 1D SDS‐PAGE followed by LC‐MS/MS of in gel digested protein. Free haemoglobin (Hb) levels were assessed by ELISA, and activity of lactate dehydrogenase (LDH), an indicator of general tissue damage, and particularly of haemolysis was measured. The proteomics analysis suggested that a 15.1‐kDa protein peak correlated with the rate of brain atrophy in seemingly all MS patients, regardless of treatment regime. Following protein enrichment, 15.1‐kDa and 15.9‐kDa peaks were observed and confirmed to represent the α‐ and β-chains of haemoglobin, respectively. In all MS patients, levels of both free Hb chains and of LDH activity were elevated compared to all controls. The results are consistent with the idea that Hb is released into serum by chronic and low‐grade intravascular haemolysis, with subsequent  translocation into the CNS where it has great potential to cause oxidative damage.    

Comments on title and abstract –

  1. We suggest that the word “associated” needs to be substituted by “correlated”

  2. Conclusions in the abstract must be linked to the objectives of the study rather than be a  speculative claim.    

Comments on study design and data interpretation – Several points require clarification, in our view.    

  1. There were 140 patents, and 60 controls (3 groups of 20). So the total number is supposed to be  200 serum samples per time point. What are the other 275 samples? The question of sample numbers, both of patients and controls, arises again later when 138 patients are mentioned. Additionally, a valuable control could be a group of patients with another neurodegenerative disease characterised by brain atrophy.    

  2. The 6‐month time point was not mentioned in the paragraph describing the study design, and there were no results reported for it.

  3. For protein profiling by SELDI‐TOF mass spectrometry, after the 1:10 serum dilution, one would  expect signal suppression effect on the lower abundance proteins. To remove this effect it would have been advised to fractionate the serum first, and then use protein chip arrays. Since the authors did not fractionate the sera, it is not possible to rule out other lower‐abundance markers, such as hemopexin, as we indicate next.

  4. The Top 12 Protein Depletion Spin Columns are a good way to partially fractionate the serum or to enrich the protein of interest. However, several very important proteins (haptoglobin, transferrin, and Apo AI) related to iron homeostasis will be removed by this procedure. In the context of this study, it is important to see the specific expression patterns of haptoglobin, hemopexin, and HO‐1 since they represent different levels of defence mechanisms against extracellular Hb. Also, it could be beneficial to try and correlate different haptoglobin phenotypes with BBSI.

  5. In the same vein, the ELISA kit will detect extracellular Hb from two sources: free Hb and haptoglobin‐bound Hb. The latter form could have been removed by the spin column that was used for protein enrichment.

  6. Why and how were only 20 patients selected for ELISA?    

Comments on discussion – We believe that the Discussion can be augmented to give a broader picture as follows.  

  1. Association versus correlation of brain volume and Hb levels. In our opinion the results show correlation between brain volume and free Hb levels and are insufficient to claim that these two factors are “associated” per se.

  2. In reference to [(Bamm and Harauz 2014)], the authors state that “neuropathological evidence does not show frequent or widespread extravascular erythrocytes in the MS brain”. This statement is not strictly correct. Firstly, in [(Bamm and Harauz 2014)] we did not suggest that chronic extravasation of red blood cells is an exclusive source of the abnormal iron deposits. In fact, we said:  “Any type of seemingly minor yet chronic cerebrovascular abnormality and/or damage to the blood– brain barrier, … , can potentially lead to intravascular hemolysis, or to extravasation of erythrocytes and extravascular hemolysis”. Secondly, as we reviewed recently [(Bamm et al. 2016)], extracellular Hb could arise from blood extravasation due to capillary and venous micro‐hemorrhages, which ARE being documented in MS lesions, as possibly are cerebral microbleeds (CBMs) [(Zivadinov et al. 2016)]. Such events can be difficult to detect at the histological level, especially in the early stages of lesion formation that can arise from molecular dysfunction rather than gross structural damage. The  potential molecular mechanisms of Hb toxicity in myelin are described in a subsequent experimental  paper [(Bamm et al. 2015)] and do not rely on large‐scale iron deposition. The damage inflicted by free Hb can arise at many different levels and per se will not necessarily be associated with the number of extravasated erythrocytes in MS tissue.

  3. In reference to erythrocyte fragility in MS, we suggest also citing one of the earlier papers to indicate that this is an old idea that has been insufficiently explored [(Caspary et al.1967)], and two newer papers that describe the association of haemoglobin variants with MS severity [(Altinoz et al. 2016; Ozcan et al. 2016)].

  4. It is not clear how the finding of higher free Hb in the sera of MS patients can be explained. The  authors reported that the mean erythrocytes count and total blood Hb did not differ between MS patients and control groups. However, the MS patients were characterized by the increased presence of free Hb. If a simple formula for total Hb is: Hb within the erythrocytes + cell‐free Hb, and the erythrocyte count was similar, then the amounts of cell‐free Hb should be similar. Is the morphology of erythrocytes from MS patients and controls different? Perhaps the erythrocytes from MS patients were hypochromic (less intracellular Hb)? We believe that the authors should clarify this  point.  

  5. The first line of defense against extracellular haemoglobin is haptoglobin (Hpt). We have determined recently that the frequency of the hpt1 allele is lower in Australia, and in European and North American countries with a high reported prevalence of MS [(Bamm et al. 2016)]. We also recommended an epidemiological study to evaluate the potential association of Hpt phenotype with disease severity and/or comorbidity with cardiovascular disorders, as is being done for Parkinsonism  [(Costa‐Mallen et al. 2015; Delanghe et al. 2016; Costa‐Mallen et al. 2016)]. It should also be pointed out that cardiovascular disorders have been found to be associated with disease severity and brain  atrophy in MS [(Kappus et al. 2016)]. This latter reference is certainly relevant to the Discussion of this current study.

We have read this submission. We believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.

References

  • 1. Altinoz MA, Ozcan EM, Ince B, Guloksuz S: Hemoglobins as new players in multiple sclerosis: metabolic and immune aspects. Metab Brain Dis.2016;31(5) : 10.1007/s11011-016-9845-7 983-92 10.1007/s11011-016-9845-7 [DOI] [PubMed] [Google Scholar]
  • 2. Bamm VV, Geist AM, Harauz G: Correlation of geographic distributions of haptoglobin alleles with prevalence of multiple sclerosis (MS) - a narrative literature review. Metab Brain Dis.2016; 10.1007/s11011-016-9923-x 10.1007/s11011-016-9923-x [DOI] [PubMed] [Google Scholar]
  • 3. Bamm VV, Harauz G: Hemoglobin as a source of iron overload in multiple sclerosis: does multiple sclerosis share risk factors with vascular disorders?. Cell Mol Life Sci.2014;71(10) : 10.1007/s00018-014-1570-y 1789-98 10.1007/s00018-014-1570-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Bamm VV, Lanthier DK, Stephenson EL, Smith GS, Harauz G: In vitro study of the direct effect of extracellular hemoglobin on myelin components. Biochim Biophys Acta.2015;1852(1) : 10.1016/j.bbadis.2014.10.009 92-103 10.1016/j.bbadis.2014.10.009 [DOI] [PubMed] [Google Scholar]
  • 5. Caspary EA, Sewell F, Field EJ: Red blood cell fragility in multiple sclerosis. Br Med J.1967;2(5552) :610-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Costa-Mallen P, Zabetian CP, Agarwal P, Hu SC, Yearout D, Samii A, Leverenz JB, Roberts JW, Checkoway H: Haptoglobin phenotype modifies serum iron levels and the effect of smoking on Parkinson disease risk. Parkinsonism Relat Disord.2015;21(9) : 10.1016/j.parkreldis.2015.07.006 1087-92 10.1016/j.parkreldis.2015.07.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Costa-Mallen P, Zabetian CP, Agarwal P, Hu SC, Yearout D, Samii A, Leverenz JB, Roberts JW, Checkoway H: Response to the letter. Parkinsonism Relat Disord.2016;22: 10.1016/j.parkreldis.2015.10.021 110-1 10.1016/j.parkreldis.2015.10.021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Delanghe JR, De Buyzere ML, Speeckaert MM, Langlois MR: Haptoglobin phenotype and Parkinson disease risk. Parkinsonism Relat Disord.2016;22(1) : http://dx.doi.org/10.1016/j.parkreldis.2015.10.020 108-109 10.1016/j.parkreldis.2015.10.020 [DOI] [PubMed] [Google Scholar]
  • 9. Kappus N, Weinstock-Guttman B, Hagemeier J, Kennedy C, Melia R, Carl E, Ramasamy DP, Cherneva M, Durfee J, Bergsland N, Dwyer MG, Kolb C, Hojnacki D, Ramanathan M, Zivadinov R: Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry.2016;87(2) : 10.1136/jnnp-2014-310051 181-7 10.1136/jnnp-2014-310051 [DOI] [PubMed] [Google Scholar]
  • 10. Ozcan ME, Ince B, Karadeli HH, Gedikbasi A, Asil T, Altinoz MA: Higher minor hemoglobin A2 levels in multiple sclerosis patients correlate with lesser disease severity. Neuropsychiatr Dis Treat.2016;12: 10.2147/NDT.S109954 2033-8 10.2147/NDT.S109954 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Zivadinov R, Ramasamy DP, Benedict RR, Polak P, Hagemeier J, Magnano C, Dwyer MG, Bergsland N, Bertolino N, Weinstock-Guttman B, Kolb C, Hojnacki D, Utriainen D, Haacke EM, Schweser F: Cerebral Microbleeds in Multiple Sclerosis Evaluated on Susceptibility-weighted Images and Quantitative Susceptibility Maps: A Case-Control Study. Radiology.2016; 10.1148/radiol.2016160060 160060 10.1148/radiol.2016160060 [DOI] [PubMed] [Google Scholar]
Wellcome Open Res. 2016 Nov 18. doi: 10.21956/wellcomeopenres.10742.r17609

Referee response for version 1

Hans Lassmann 1, Simon Hametner 1

This is a very interesting study providing convincing evidence for an association between the serum level increases of free haemoglobin with the extent of brain atrophy progression, determined by MRI, in secondary progressive multiple sclerosis. This was originally observed by the authors using an unbiased proteomics approach, aimed at determining potential serum biomarkers for disease progression. The patient collective derives from a well-controlled clinical trial investigating the effect of simvastatin on the rate of brain atrophy progression in secondary progressive MS. Having found this association, the authors then confirmed free hemoglobin increase in SPMS patients by an independent approach using ELISA.

The study is very well performed, based on a sound and innovative technology and the results have major implications for the understanding of the neurodegenerative process in MS. Interestingly, the association between haemoglobin serum level increase and atrophy rate occurred independently from the effect of simvastatin treatment. Thus increased haemoglobin in the serum may contribute to the neurodegenerative process, but there are other mechanisms additionally involved. By showing also increased levels of serum LDH the authors further support the concept that there is a low degree of hemolysis in the peripheral blood of MS patients, which however is not reflected in reduction of erythrocyte counts, haematocrit or total blood haemoglobin. However, it would also be interesting to address whether there is an association between actual free hemoglobin levels at any of the single time points (not their change over time), as determined by mass spectrometry, and the observed brain atrophy rates. Authors only show a positive association of free hemoglobin increase with brain atrophy levels, which might have a different interpretation than what the authors conclude. Furthermore, the quantitative ELISA data are not linked with MRI brain atrophy rates. Were the 20 MS patients included in the ELISA quantification taken from the big cohort of the proteomics part of the study? Then MRI data would be available, and the analysis could be easily performed.

There is good indirect evidence that iron loading of the brain may be involved in neurodegeneration in MS through the amplification of oxidative injury. So far, the mechanisms how the human brain is loaded with iron during aging and in the disease process of MS is not fully understood. This study indicates that heme iron, derived from free circulating haemoglobin, may be of major importance in brain iron accumulation in the course of multiple sclerosis. Free hemoglobin, presumably bound to the haemoglobin scavenger haptoglobin, might diffuse into the brain via a partially compromised blood-brain barrier and might lead to iron accumulation within MS basal ganglia and microglia at edges of chronic lesions. The key question, which however remains unresolved here, concerns the cause of increased free haemoglobin in the blood of MS patients. Interestingly, it has already been shown in the late 1960ths that erythrocyte diameters are larger in MS patients (J. Prineas,1968) and that there is a higher fragility of erythrocytes in comparison to controls, which may result in liberation of haemoglobin (E.A. Caspary et al.,1967). These observations together with more recent findings, which relate them to other disturbances of iron homeostasis in MS, have been recently discussed in a comprehensive review article (Altinoz et al., 2016). Whether the increased erythrocyte fragility is a genuine metabolic problem or a consequence of a general systemic chronic pro-inflammatory environment in the MS patients is currently unresolved.

We have read this submission. We believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

References

  • 1. Altinoz MA, Ozcan EM, Ince B, Guloksuz S: Hemoglobins as new players in multiple sclerosis: metabolic and immune aspects. Metab Brain Dis.2016;31(5) : 10.1007/s11011-016-9845-7 983-92 10.1007/s11011-016-9845-7 [DOI] [PubMed] [Google Scholar]
  • 2. Caspary EA, Sewell F, Field EJ: Red blood cell fragility in multiple sclerosis. Br Med J.1967;2(5552) :610-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Prineas J: Red blood cell size in multiple sclerosis. Acta Neurol Scand.1968;44(1) :81-90 [DOI] [PubMed] [Google Scholar]

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Click here for additional data file. (245.5KB, tgz)

    Data Availability Statement

    Zenodo: Raw data for SELDI-TOF low range from article: Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis, http://doi.org/10.5281/zenodo.160737 32

    Zenodo: Raw data for SELDI-TOF high range from article: Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis, http://doi.org/10.5281/zenodo.160743 33

    Zenodo: Nano LC MS-MS peptide matches from article: Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis, http://doi.org/10.5281/zenodo.160744 34

    Zenodo: Raw data for RBC, Hb and haematocrit from article: Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis, http://doi.org/10.5281/zenodo.161532 35

    Articles from Wellcome Open Research are provided here courtesy of The Wellcome Trust

    RESOURCES